CagriSema: Novo Nordisk's Next-Generation GLP-1/Amylin Combination
Novo Nordisk's response to retatrutide isn't a triple agonist — it's a combination therapy. CagriSema pairs proven semaglutide with cagrilintide, an amylin receptor agonist targeting a completely different appetite pathway.
While Eli Lilly pursues the triple-agonist approach with retatrutide, Novo Nordisk is betting on a different strategy: combining semaglutide with cagrilintide, a long-acting amylin receptor agonist. The combination, marketed as CagriSema, targets two independent appetite-regulation pathways simultaneously.
The Mechanism: Why Amylin Matters
Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells. It provides a complementary satiety signal through several mechanisms:
- Area postrema signaling: Amylin activates receptors in the area postrema (a brainstem region outside the blood-brain barrier), producing nausea-independent satiety
- Glucagon suppression: Reduces post-meal glucagon secretion, lowering hepatic glucose output
- Gastric emptying: Slows gastric emptying through a distinct pathway from GLP-1
- Caloric intake reduction: Preclinical data shows amylin receptor activation reduces food intake through pathways that don't overlap with GLP-1 signaling
The rationale for combining semaglutide + cagrilintide is pharmacological non-redundancy: two drugs hitting two different appetite-regulation systems should produce greater effect than either alone, without simply doubling the GI side effects.
Phase 2 Data
CagriSema Phase 2 results showed approximately 15–17% weight loss at the highest doses tested over relatively short treatment durations. The combination appeared to produce additive weight loss compared to semaglutide alone, though the magnitude of the additive effect varied across dose combinations.
Phase 3: What to Expect
The Phase 3 program targets approximately 25% weight loss — enough to compete with tirzepatide's ~22.5% (SURMOUNT-1) and positioned between tirzepatide and retatrutide's 28.3% (TRIUMPH-1). Full Phase 3 results are expected in 2026.
The competitive positioning is strategic: CagriSema uses the same semaglutide backbone that has the most extensive safety database of any GLP-1 (including cardiovascular and kidney outcome trials). This reduces the NDA risk compared to an entirely novel molecule like retatrutide.
CagriSema vs. Retatrutide: Different Bets
| Feature | CagriSema | Retatrutide |
|---|---|---|
| Mechanism | GLP-1 + amylin | GLP-1 + GIP + glucagon |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Expected efficacy | ~25% weight loss | 28.3% (TRIUMPH-1) |
| Safety backbone | Semaglutide (extensive data) | Novel compound (limited data) |
| GI tolerability | Expected moderate | Higher AE rate, 18% discontinuation |
| Phase 3 status | Ongoing, results expected 2026 | TRIUMPH-1 reported May 2026 |
| Novel safety signal | None identified (known compounds) | Dysesthesia (20.9% in TRIUMPH-4) |
Novo is betting that the proven semaglutide safety profile, combined with amylin's complementary mechanism, will produce 25% weight loss with better tolerability than retatrutide's 28.3% — and that the 3 percentage point efficacy gap will be offset by a more favorable risk-benefit ratio.
The Bottom Line
CagriSema represents Novo Nordisk's answer to the "next generation beyond tirzepatide" question. By pairing semaglutide with the amylin analog cagrilintide, it targets a novel appetite pathway without introducing the glucagon-related tolerability concerns seen with retatrutide. Phase 3 results in 2026 will determine whether the combination lives up to its ~25% efficacy target and whether the tolerability advantage is real.
Sources
- Novo Nordisk. CagriSema Phase 2 data. Clinical trial presentations.
- Novo Nordisk. CagriSema Phase 3 program overview.
- Hay DL et al. "Amylin: pharmacology, physiology, and clinical potential." Pharmacol Rev. 2015.
- Eli Lilly. TRIUMPH-1 topline results. May 21, 2026.